Clinical Interests of Circulating Tumor DNA in Oncology
Genetic alterations in tumors, as predictor of response to targeted-therapies or as prognostic markers, are clinically relevant to determine adequate therapeutic management. Tumor biopsy is currently the golden standard for somatic alterations assessment, but this approach is invasive and does not consider tumor heterogeneity. In various body fluids like plasma, somatic mutations have been identified. Circulating tumor DNA (ctDNA) holds promises in tumor burden monitoring or malignancies early detection.
Source: Archives of Medical Research - Category: Research Authors: Claire Franczak, Pierre Filhine-Tressarieu, Julien Bros éus, Pauline Gilson, Jean-Louis Merlin, Alexandre Harlé Tags: Review Article Source Type: research